Elkholy Rasha A, Fouda Mohamed H, Elhawary Eslam E, Elkholy Reem A, Elshora Ola A
Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
Pediatrics Department, Faculty of Medicine, Tanta University, Tanta, Egypt.
J Blood Med. 2021 Mar 16;12:147-156. doi: 10.2147/JBM.S300067. eCollection 2021.
CD105 (Endoglin) is a receptor of the transforming growth factor-Beta (TGF- β) superfamily. It is expressed in angiogenic endothelial cells and is considered a powerful marker of angiogenesis and a potential main player in the pathogenesis of vascular diseases as well as tumor progression. CD105 expression was correlated with poor prognosis in many types of solid malignancies, however, its influence on hematological neoplasms is still an area of interest.
To assess the flow-cytometric expression of CD105 in childhood B-acute lymphoblastic leukemia (B-ALL) and its relation to disease response after the induction chemotherapy.
Eighty children newly diagnosed with B-ALL were screened for flow-cytometric expression of CD105 at time of diagnosis, then they were followed up to detect their response to induction therapy.
CD105 was expressed in 41.2% of B-ALL patients. Higher expression of CD105 was observed in high and very high-risk groups. The multivariate analysis considered CD105 positivity as an independent prognostic marker for response to induction therapy. Values higher than 2.5 Specific fluorescence indices (SFIs) and 35% expression were sensitive predictors to induction failure.
CD105 can be considered as a potential prognostic marker for the detection of response to induction therapy in childhood B-ALL, and it can serve to optimize treatment decisions.
CD105（内皮糖蛋白）是转化生长因子-β（TGF-β）超家族的一种受体。它在血管生成的内皮细胞中表达，被认为是血管生成的有力标志物，也是血管疾病以及肿瘤进展发病机制中的一个潜在主要因素。在许多类型的实体恶性肿瘤中，CD105表达与预后不良相关，然而，其对血液系统肿瘤的影响仍是一个研究热点。
评估儿童B淋巴细胞急性淋巴细胞白血病（B-ALL）中CD105的流式细胞术表达情况及其与诱导化疗后疾病反应的关系。
对80例新诊断的B-ALL患儿在诊断时进行CD105流式细胞术表达筛查，然后对他们进行随访以检测其对诱导治疗的反应。
41.2%的B-ALL患者表达CD105。在高危和极高危组中观察到CD105的高表达。多变量分析将CD105阳性视为诱导治疗反应的独立预后标志物。高于2.5个特异性荧光指数（SFIs）和35%表达的值是诱导失败的敏感预测指标。
CD105可被视为检测儿童B-ALL诱导治疗反应的潜在预后标志物，它有助于优化治疗决策。
